Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
or
Menu

Moleculin Biotech CS (MBRX)

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 39,881
  • Shares Outstanding, K 27,130
  • Annual Sales, $ 0 K
  • Annual Income, $ -9,810 K
  • 36-Month Beta 1.85
  • Price/Sales N/A
  • Price/Cash Flow N/A
  • Price/Book 2.66

Analyst Rating / Earnings Estimates

Current Rating
See More
Strong Buy
Based on 1 analysts offering recommendations.
Earnings Estimates - Current Qtr 12/31/18
See More
  • Average Estimate -0.10
  • Number of Estimates 1
  • High Estimate -0.10
  • Low Estimate -0.10
  • Prior Year -0.17
  • Growth Rate Est. (year over year) +41.18%

Price Performance

See More
Period Period Low Period High Performance
1-Month
1.30 +13.08%
on 01/23/19
1.73 -15.03%
on 02/05/19
+0.05 (+3.52%)
since 01/15/19
3-Month
0.93 +58.06%
on 12/21/18
1.73 -15.03%
on 02/05/19
+0.09 (+6.52%)
since 11/15/18
52-Week
0.93 +58.06%
on 12/21/18
2.43 -39.51%
on 06/20/18
-1.33 (-47.50%)
since 02/15/18

Most Recent Stories

More News
Paramount Developments Crucial for Advancing Clinical Trials Targeting Cancer Treatments

The biotech drug industry, with encouragement from the Food and Drug Administration (FDA), is advancing efforts to modernize clinical trials, streamlining the process of figuring out whether a treatment...

MGNX : 21.84 (+3.41%)
CLVS : 25.49 (+0.08%)
NVLN : 1.34 (-1.47%)
PFE : 42.40 (+1.02%)
MBRX : 1.47 (unch)
4 Healthcare Stocks The Market is Watching on Tuesday (2/5/19)

CORAL GABLES, FL / ACCESSWIRE / February 5, 2019 / The market has been a hotbed of excitement over the course of the past couple of years as companies across the healthcare industry have employed more...

CLDX : 5.86 (+13.35%)
TDOC : 69.43 (+4.28%)
PHGI.CN : 0.830 (unch)
PHGRF : 0.6316 (+1.95%)
MBRX : 1.47 (unch)
Cancer Drug Development Shows That Government and Private Sector can Work Together

Considering that yesterday, February 4, was World Cancer Day, it is encouraging that the private sector and the U.S. government are mutually trying to solve a serious problem and are in fact, working closely...

EOLS : 27.38 (+0.44%)
AGEN : 3.61 (+1.98%)
TTNP : 1.53 (-1.92%)
QGEN : 38.64 (+1.18%)
MBRX : 1.47 (unch)
Moleculin Announces the FDA has Granted Orphan Drug Designation for its Brain Tumor Drug

Moleculin Biotech, Inc., (Nasdaq: MBRX) ("Moleculin" or the "Company"), a clinical stage pharmaceutical company focused on the development of oncology drug candidates, all of which are based on license...

MBRX : 1.47 (unch)
Moleculin Announces Dr. James L. Abbruzzese, Chief of Medical Oncology Division at Duke University, Joins Science Advisory Board

Moleculin Biotech, Inc., (Nasdaq: MBRX) ("Moleculin" or the "Company"), a clinical stage pharmaceutical company focused on the development of oncology drug candidates, all of which are based on license...

MBRX : 1.47 (unch)
Why Clinical Trial Advantages and Regulatory Process in EU may Hold Advantages Over the U.S.

Financialnewsmedia.com News Commentary

LJPC : 6.23 (+4.88%)
MRNA : 21.44 (+9.05%)
PFE : 42.40 (+1.02%)
MBRX : 1.47 (unch)
AXSM : 9.33 (+1.74%)
Moleculin Announces Patient Recruitment Begins in Annamycin Clinical Trial In Poland

Received European approval to ship Annamycin into Poland to start treating patients

MBRX : 1.47 (unch)
Amarin Down on Lower '19 View, Posts Preliminary '18 Results

Amarin (AMRN) reports preliminary results for 2018 and issues guidance for 2019. While the results exceeded estimates, outlook missed the same.

AMRN : 17.66 (+1.79%)
MRUS : 11.36 (-4.86%)
NCNA : 11.72 (+3.63%)
MBRX : 1.47 (unch)
Moleculin Announces Positive Data for its Pancreatic Cancer Drug Candidate

Moleculin Biotech, Inc., (Nasdaq: MBRX) ("Moleculin" or the "Company"), a clinical stage pharmaceutical company focused on the development of oncology drug candidates, all of which are based on license...

MBRX : 1.47 (unch)
Report: Exploring Fundamental Drivers Behind Cronos Group, Henry Schein, Argo Group International, Eiger BioPharmaceuticals, China Automotive, and Moleculin Biotech -- New Horizons, Emerging Trends, and Upcoming Developments

In new independent research reports released early this morning, Market Source Research released its latest key findings for all current investors, traders, and shareholders of Cronos Group Inc. (NASDAQ:CRON),...

CRON : 21.29 (+2.26%)
HSIC : 62.39 (+0.03%)
ARGO : 68.45 (+1.69%)
AGII : 58.85 (+5.37%)
EIGR : 13.28 (-0.23%)
CAAS : 3.18 (-9.66%)
MBRX : 1.47 (unch)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 40% Buy with a Weakest short term outlook on maintaining the current direction.

Longer term, the trend strength is Weak.

See More Share

Trade MBRX with:

Business Summary

Moleculin Biotech, Inc. is a preclinical and clinical-stage pharmaceutical company which focused on the development of anti-cancer drug candidates. The company's lead product candidate is Annamycin, a Phase II clinical stage anthracycline for the treatment of relapsed or refractory acute myeloid leukemia....

See More

Key Turning Points

2nd Resistance Point 1.54
1st Resistance Point 1.50
Last Price 1.47
1st Support Level 1.44
2nd Support Level 1.42

See More

52-Week High 2.43
Fibonacci 61.8% 1.86
Fibonacci 50% 1.68
Fibonacci 38.2% 1.50
Last Price 1.47
52-Week Low 0.93

See More

Add Data Columns to this Table
Learn about our Custom Views
Want to use this as
your default charts setting?
Learn about our Custom Templates
Switch the Market flag
above for targeted data.
Open the menu and switch the
Market flag for targeted data.
Get Streaming Chart Updates
Switch your Site Preferences
to Interactive Chart
Read About Upcoming
Changes to This Feature
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar